JP2017533946A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533946A5
JP2017533946A5 JP2017526527A JP2017526527A JP2017533946A5 JP 2017533946 A5 JP2017533946 A5 JP 2017533946A5 JP 2017526527 A JP2017526527 A JP 2017526527A JP 2017526527 A JP2017526527 A JP 2017526527A JP 2017533946 A5 JP2017533946 A5 JP 2017533946A5
Authority
JP
Japan
Prior art keywords
methyl
amino
carboxamide
pyrazine
oxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533946A (ja
JP6779204B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/060509 external-priority patent/WO2016081290A1/en
Publication of JP2017533946A publication Critical patent/JP2017533946A/ja
Publication of JP2017533946A5 publication Critical patent/JP2017533946A5/ja
Application granted granted Critical
Publication of JP6779204B2 publication Critical patent/JP6779204B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526527A 2014-11-18 2015-11-13 A2a拮抗薬特性を有するアミノピラジン化合物 Expired - Fee Related JP6779204B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081262P 2014-11-18 2014-11-18
US62/081,262 2014-11-18
PCT/US2015/060509 WO2016081290A1 (en) 2014-11-18 2015-11-13 Aminopyrazine compounds with a2a antagonist properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020138418A Division JP2020193211A (ja) 2014-11-18 2020-08-19 A2a拮抗薬特性を有するアミノピラジン化合物

Publications (3)

Publication Number Publication Date
JP2017533946A JP2017533946A (ja) 2017-11-16
JP2017533946A5 true JP2017533946A5 (enExample) 2018-12-20
JP6779204B2 JP6779204B2 (ja) 2020-11-04

Family

ID=56014406

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017526527A Expired - Fee Related JP6779204B2 (ja) 2014-11-18 2015-11-13 A2a拮抗薬特性を有するアミノピラジン化合物
JP2020138418A Withdrawn JP2020193211A (ja) 2014-11-18 2020-08-19 A2a拮抗薬特性を有するアミノピラジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020138418A Withdrawn JP2020193211A (ja) 2014-11-18 2020-08-19 A2a拮抗薬特性を有するアミノピラジン化合物

Country Status (11)

Country Link
US (1) US10472347B2 (enExample)
EP (1) EP3220910B1 (enExample)
JP (2) JP6779204B2 (enExample)
KR (1) KR20170083136A (enExample)
CN (1) CN107106558A (enExample)
AU (1) AU2015350315B2 (enExample)
BR (1) BR112017010261A2 (enExample)
CA (1) CA2967944C (enExample)
MX (1) MX381180B (enExample)
RU (1) RU2727805C2 (enExample)
WO (1) WO2016081290A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4302834A3 (en) * 2016-07-12 2024-07-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ,インコーポレイテッド アロステリックshp2阻害剤としての二環式化合物
EP3594216B1 (en) * 2017-03-07 2022-04-06 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof
CN111163780A (zh) 2017-07-18 2020-05-15 诺维逊生物股份有限公司 作为腺苷拮抗剂的杂环化合物
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
JP2020532541A (ja) 2017-08-31 2020-11-12 コーバス・ファーマシューティカルズ・インコーポレイテッド アデノシンa2b受容体およびアデノシンa2a受容体を調節するための化合物および方法
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構shp2抑制劑的吡啶、吡嗪和三嗪化合物
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
JP7361693B2 (ja) 2017-12-15 2023-10-16 レヴォリューション・メディスンズ,インコーポレイテッド アロステリックshp2阻害剤としての多環式化合物
WO2020037094A1 (en) 2018-08-16 2020-02-20 Innate Tumor Immunity, Inc. Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
EP3616753A1 (en) * 2018-08-31 2020-03-04 Corvus Pharmaceuticals, Inc. Compounds for modulating adenosine a2b receptor and adenosine a2a receptor
US12414952B2 (en) 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019383948A1 (en) 2018-11-20 2021-05-20 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020112700A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019388872A1 (en) 2018-11-30 2021-05-27 Merck Sharp & Dohme Llc 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
WO2020150676A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
AU2020208644A1 (en) 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
TW202128650A (zh) * 2019-10-11 2021-08-01 德商拜耳動物保健有限公司 作為殺蟲劑之新穎的雜芳基取代之吡𠯤衍生物
CN111285798A (zh) * 2020-04-09 2020-06-16 阿里生物新材料(常州)有限公司 一种(3-环丙基吡啶-2-基)甲胺盐酸盐的合成方法
CN111423364A (zh) * 2020-05-19 2020-07-17 阿里生物新材料(常州)有限公司 一种(3-环丙基吡啶-2-基)甲胺的合成方法
EP3929189A1 (en) * 2020-06-25 2021-12-29 Bayer Animal Health GmbH Novel heteroaryl-substituted pyrazine derivatives as pesticides
TW202304865A (zh) 2021-03-23 2023-02-01 美商百愛及生物醫藥公司 Nlrp3發炎體之抑制劑
CN119053602A (zh) 2022-01-28 2024-11-29 柏奥艾奇实验室公司 Nlrp3炎性体的n-氧化物抑制剂
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ, インコーポレイテッド Trop-2発現がんを治療するための併用療法
US12516018B2 (en) * 2023-03-30 2026-01-06 Brandeis University Solid-solid phase change aromatic azo compounds, method of manufacture, and use for thermal energy storage and release
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US12509459B2 (en) 2024-03-26 2025-12-30 BioAge Labs, Inc. Inhibitors of NLRP3 inflammasome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
WO1995003806A1 (en) 1993-07-27 1995-02-09 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
DE60110219T2 (de) 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
CA2527033A1 (en) * 2003-06-18 2004-12-23 Astrazeneca Ab 2-substitued 5,6-diaryl-pyrazine derivatives as cb1 modulators
CA2543644A1 (en) * 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
US20060199828A1 (en) * 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
ES2270715B1 (es) * 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
EP2438041A4 (en) * 2009-06-01 2012-11-21 Merck Sharp & Dohme PYRAZINE-carboxamide-orexin receptor Antagonist

Similar Documents

Publication Publication Date Title
JP2017533946A5 (enExample)
RU2017120853A (ru) Аминопиразиновые соединения со свойствами антагониста a2a
KR101819433B1 (ko) 인돌린-2-온 또는 피롤로-피리딘-2-온 유도체
JP4672820B2 (ja) GABAα5リガンドとしての置換1,2,4−トリアゾロ[3,4−a]フタラジン誘導体
US9321756B2 (en) Azole compounds as PIM inhibitors
MX2011012345A (es) Inhibidores de pi3k/mtor basados en benzoxazepinas contra enfermedades proliferativas.
CN111556871B (zh) 作为PDE1抑制剂的1H-吡唑并[4,3-b]吡啶
JP2016500073A5 (enExample)
JP2013527173A5 (enExample)
JP2013508404A5 (enExample)
JP2017530960A5 (enExample)
RU2007101544A (ru) Антагонисты рецепторов высвобождающего гонадотропин гормона
JP2013508403A5 (enExample)
WO2010126895A1 (en) Inhibitors of pi3 kinase and / or mtor
ME02802B (me) P2x7 modulatori
CN120826403A (zh) Shp2抑制剂化合物及其应用
AU2011338389A1 (en) Bicyclic compounds as Pim inhibitors
JP2013508405A5 (enExample)
DK2491038T3 (da) Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
RU2015114936A (ru) Ингибиторы серин/треонинкиназы
KR101898364B1 (ko) 인돌린-2-온 및 1,3-다이하이드로-피롤로[3,2-c]피리딘-2-온 유도체
KR20150047609A (ko) 피리딘 유도체 및 의약
CN114502537A (zh) 突变型idh2抑制剂及其应用
RU2015125306A (ru) Новые соединения ингибиторы фосфодиэстеразы типа 10а
WO2026076218A1 (en) Mrgprx2 antagonists and methods of use thereof